journal article·2018

Selective delivery of adapalene to the human hair follicle under finite dose conditions using polymeric micelle nanocarriers

Somnath G. Kandekar, Sergio del Río-Sancho, Maria Lapteva, Yogeshvar N. Kalia

Nanoscale· Volume 10· Issue 3
Publisher page

Abstract

Drug delivery systems that target the pilosebaceous unit (PSU) selectively could improve the clinical management of diseases that originate in the hair follicle. The aims of this study were (i) to prepare polymeric micelles using d-α-tocopheryl polyethylene glycol succinate diblock copolymer that incorporated adapalene (ADA), a retinoid indicated for Acne vulgaris, and (ii) to investigate the feasibility of delivering ADA preferentially to the PSU under finite dose conditions - thereby better approximating actual conditions of use by patients. Incorporation of ADA into spherical micelles (dn <20 nm) increased aqueous solubility by ∼50 000-fold (from <4 ng mL-1 to 0.2 mg mL-1). Optimized micelle solution and gel formulations (0.02% ADA) were stable after storage for 4 weeks at 4 °C. Finite dose experiments using full-thickness porcine and human skin revealed that ADA delivery efficiency from micelle solution and gel formulations was equivalent and was >2- and 10-fold higher than that from Differin® gel and Differin® cream (products containing ADA at 0.1% (w/w)). Follicular delivery studies in human skin, using a punch biopsy technique to extract the intact PSU, demonstrated that the micelle solution and gel formulations did indeed enable preferential delivery of ADA to the PSU (4.5- and 3.3-fold higher, respectively, than that to PSU-free skin biopsies). Confocal laser scanning microscopy provided visual corroboration that ADA was uniformly distributed in the hair follicles. In conclusion, the results confirmed that polymeric micelle nanocarriers enabled selective, targeted drug delivery to the PSU under finite dose conditions and so might improve therapy of follicular diseases and decrease off-site side-effects.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Hair Growth and Disorders · Advancements in Transdermal Drug Delivery · Acne and Rosacea Treatments and Effects

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmaceutical Sciences

University of Geneva & University of Lausanne

1211 Geneva

Switzerland

References (48)

Show source-provided references
1. Bernard · Skin Pharmacol. · 1993 · 6 · 6110.1159/000211165 ↗
2. Castro · Expert Opin. Drug Delivery · 2008 · 5 · 66510.1517/17425247.5.6.665 ↗
3. Gollnick · J. Am. Acad. Dermatol. · 2003 · 49 · S110.1067/mjd.2003.618 ↗
4. Ramezanli · Nanomedicine · 2017 · 13 · 14310.1016/j.nano.2016.08.008 ↗
5. Harde · RSC Adv. · 2015 · 5 · 4391710.1039/C5RA06047H ↗
6. Kumar · Drug Dev. Ind. Pharm. · 2016 · 42 · 87110.3109/03639045.2015.1082580 ↗
7. Jain · Colloids Surf., B · 2014 · 121 · 22210.1016/j.colsurfb.2014.05.041 ↗
8. Jain · Drug Dev. Ind. Pharm. · 2016 · 42 · 89710.3109/03639045.2015.1104343 ↗
9. Schmook · Int. J. Pharm. · 2001 · 215 · 5110.1016/S0378-5173(00)00665-7 ↗
10. Abd · Clin. Pharmacol.: Adv. Appl. · 2016 · 8 · 163
11. Guo · Pharm. Res. · 2014 · 31 · 305110.1007/s11095-014-1398-z ↗
12. Kalia · Adv. Drug Delivery Rev. · 2001 · 48 · 15910.1016/S0169-409X(01)00113-2 ↗
13. M. S. Roberts , Y. G.Anissimov and R. A.Gonsalvez , in Percutaneous absorption: drugs, cosmetics, mechanisms, methodology , ed. R. L. Bronaugh and H. I. Maibach , CRC Press , New York, USA , 3rd edn, 1999 , ch. 1, pp. 1–49
14. OECD , Guidance document for the conduct of skin absorption studies, http://www.oecd-ilibrary.org/environment/guidance-document-for-the-conduct-of-skin-absorption-studies_9789264078796-en
15. Schäfer-Korting · Clin. Invest. · 1994 · 72 · 108610.1007/BF00577761 ↗
16. A. F. Davis , in Dermatologic, cosmeceutic, and cosmetic development , ed. K. A. Walters and M. S. Roberts , Informa Healthcare USA, Inc. , New York, USA , 2008 , ch. 12, pp. 197–213
17. Roberts · J. Controlled Release · 2017 · 247 · 8610.1016/j.jconrel.2016.12.022 ↗
18. Papakostas · Arch. Dermatol. Res. · 2011 · 303 · 53310.1007/s00403-011-1163-7 ↗
19. Bachhav · J. Controlled Release · 2011 · 153 · 12610.1016/j.jconrel.2011.03.003 ↗
20. Lapteva · Mol. Pharmaceutics · 2014 · 11 · 298910.1021/mp400639e ↗
21. Lapteva · J. Controlled Release · 2014 · 196 · 910.1016/j.jconrel.2014.09.021 ↗
22. Lapteva · Nanoscale · 2015 · 7 · 1865110.1039/C5NR04770F ↗
23. Gabriel · J. Controlled Release · 2016 · 242 · 1610.1016/j.jconrel.2016.09.007 ↗
24. Kahraman · Colloids Surf., B · 2016 · 146 · 69210.1016/j.colsurfb.2016.07.029 ↗
25. C. Surber and E.Smith , in Dermatopharmacology of topical preparations: a product development-oriented approach , ed. B. Gabard , C. Surber , P. Elsner and P. Treffel , Springer , Berlin Heidelberg , 2000 , ch. 2, pp. 5–21
26. Guo · Eur. J. Pharm. Sci. · 2013 · 49 · 17510.1016/j.ejps.2013.02.006 ↗
27. Zhang · Biomaterials · 2012 · 33 · 488910.1016/j.biomaterials.2012.03.046 ↗
28. Varma · Eur. J. Pharm. Sci. · 2005 · 25 · 44510.1016/j.ejps.2005.04.003 ↗
29. Muthu · Nanomedicine · 2012 · 7 · 35310.2217/nnm.11.111 ↗
30. Vadlapudi · J. Ocul. Pharmacol. Ther. · 2013 · 30 · 4910.1089/jop.2013.0157 ↗
31. USFDA , Differin gel product information, http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020380s004lbl.pdf
32. USFDA , Differin cream product information, http://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20748lbl.pdf
33. Lademann · Skin Pharmacol. Physiol. · 2006 · 19 · 23210.1159/000093119 ↗
34. Morales · Nanomedicine · 2015 · 10 · 25310.2217/nnm.14.159 ↗
35. Lukyanov · Adv. Drug Delivery Rev. · 2004 · 56 · 127310.1016/j.addr.2003.12.004 ↗
36. P. Alexandridis and B.Lindman , Amphiphilic block copolymers: self-assembly and applications , Elsevier Science B.V. , Amsterdam , 2000
37. Duhem · J. Controlled Release · 2014 · 182 · 3310.1016/j.jconrel.2014.03.009 ↗
38. Patzelt · Expert Opin. Drug Delivery · 2013 · 10 · 78710.1517/17425247.2013.776038 ↗
39. Lademann · Eur. J. Pharm. Biopharm. · 2011 · 77 · 46510.1016/j.ejpb.2010.10.015 ↗
40. Torchilin · J. Controlled Release · 2001 · 73 · 13710.1016/S0168-3659(01)00299-1 ↗
41. A. Naik , Y. N.Kalia , F.Pirot and R. H.Guy , in Percutaneous absorption: drugs, cosmetics, mechanisms, methodology , ed. R. L. Bronaugh and H. I. Maibach , CRC Press , New York, USA , 3rd edn, 1999 , ch. 8, pp. 149–176
42. Oliveira · Int. J. Pharm. · 2012 · 435 · 3810.1016/j.ijpharm.2012.05.037 ↗
43. Kim · J. Invest. Dermatol. · 2000 · 114 · 34910.1046/j.1523-1747.2000.00868.x ↗
44. Mukherjee · Clin. Interventions Aging · 2006 · 1 · 32710.2147/ciia.2006.1.4.327 ↗
45. Orfanos · Drugs · 1997 · 53 · 35810.2165/00003495-199753030-00003 ↗
46. Barry · Br. J. Dermatol. · 1976 · 95 · 42310.1111/j.1365-2133.1976.tb00844.x ↗
47. Griffiths · Arch. Dermatol. · 1995 · 131 · 103710.1001/archderm.1995.01690210067011 ↗
48. Nyirady · Cutis · 2001 · 68 · 135